GERON CORP Proceeds from Long-Term Debt Issued
GERON CORP (GERN) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-03-02
- GERON CORP proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $14.89M.
- GERON CORP proceeds from issuance of long-term debt for the quarter ending 2021-09-30 was $0.00.
- GERON CORP proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was -$692.00K.
- GERON CORP proceeds from issuance of long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- GERON CORP proceeds from issuance of long-term debt for fiscal 2024 was $121.12M, a 307.81% increase from fiscal 2023.
- GERON CORP proceeds from issuance of long-term debt for fiscal 2023 was $29.70M.
- GERON CORP proceeds from issuance of long-term debt for fiscal 2021 was $24.89M, a 4.32% increase from fiscal 2020.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $121.12M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $29.70M 10-K · filed 2026-03-02 | |||
| 2021-12-31 | $14.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $14.89M derived: sum of 2 quarters · filed 2024-02-28 | $24.89M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $10.00M 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $10.00M 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | -$692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $23.86M 10-K · filed 2023-03-16 | ||
| 2020-09-30 | $24.55M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |